Technology
Health
Biotechnology

Entasis Therapeutics

$6.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (1.44%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ETTX and other stocks, options, ETFs, and crypto commission-free!

About

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. Read More The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.

Employees
33
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
83.23M
Price-Earnings Ratio
Dividend Yield
Average Volume
47.75K
High Today
$6.45
Low Today
$6.16
Open Price
$6.45
Volume
1.70K
52 Week High
$13.70
52 Week Low
$3.97

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO

News

NasdaqApr 30

Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit being held May 7-9, 2019 in New York, New York. Investors attending t...

11

Earnings

-$20.00
-$13.60
-$7.20
-$0.80
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.80 per share
Actual
-$0.99 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.